Suggested remit: To appraise the clinical and cost effectiveness of upadacitinib within its marketing authorisation for treatment of active non-radiographic axial spondyloarthritis.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA
ID number 3958

Provisional Schedule

Committee meeting: 1 08 November 2022
Expected publication 31 January 2023

Project Team

Project lead Thomas Feist

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ

Stakeholders

Companies sponsors AbbVie
Others Department of Health and Social Care
  NHS England & NHS Improvement
  Welsh Government
Patient carer groups National Ankylosing Spondylitis Society
Professional groups British Society for Rheumatology
  Royal College of Physicians
Comparator companies Eli Lilly
  Novartis
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
10 March 2022 Invitation to participate
10 March 2022 In progress. ITP scheduled
09 November 2021 - 07 December 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual